These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33547683)

  • 1. Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.
    Ang MK; Montoya JE; Tharavichitkul E; Lim C; Tan T; Wang LY; Wee J; Soong YL; Fong KW; Ng QS; Tan DS; Toh CK; Tan EH; Lim WT
    Head Neck; 2021 May; 43(5):1641-1651. PubMed ID: 33547683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
    Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
    Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Thai Hoa NT; Quang Huy H
    Cureus; 2020 May; 12(5):e8105. PubMed ID: 32426197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Yamamoto N; Harada H; Okamoto I; Masuda N; Hayakawa K; Satouchi M; Soejima T; Nishio M; Kozuka T; Takeda K; Tanaka M; Seto T; Sasaki T; Tsubouchi H; Kakurai Y; Nishimura Y; Nakagawa K
    Clin Lung Cancer; 2021 Mar; 22(2):134-141. PubMed ID: 33518480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
    Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
    Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
    Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
    Ueki Y; Ohshima S; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Saijo K; Tanaka R; Togashi T; Sato Y; Takano S; Omata J; Takahashi N; Okabe R; Horii A
    Int J Clin Oncol; 2024 Jan; 29(1):20-26. PubMed ID: 37843751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
    Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
    Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.
    Reddy BK; Lokesh V; Vidyasagar MS; Shenoy K; Babu KG; Shenoy A; Naveen T; Joseph B; Bonanthaya R; Nanjundappa ; Bapsy PP; Loknatha ; Shetty J; Prasad K; Tanvir Pasha CR
    Oral Oncol; 2014 May; 50(5):498-505. PubMed ID: 24613543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
    Menon N; Patil V; Noronha V; Joshi A; Bhattacharjee A; Satam BJ; Mathrudev V; Ghosh Laskar S; Prabhash K
    Oral Oncol; 2021 Nov; 122():105517. PubMed ID: 34560383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nimotuzumab plus chemotherapy with docetaxel, cisplatin, 5-fluorouracil for locally advanced head and neck squamous cell carcinoma: A clinical study.
    Wang X; Gu J; Shao C; Han K; Meng J
    J Cancer Res Ther; 2019; 15(2):312-316. PubMed ID: 30964103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
    Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
    J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
    Mizumachi T; Homma A; Kakizaki T; Sakashita T; Kano S; Hatakeyama H; Tsuchiya K; Yasuda K; Onimaru R; Shirato H; Taguchi J; Shimizu Y; Kinoshita I; Akita H; Fukuda S
    Int J Clin Oncol; 2015 Jun; 20(3):431-7. PubMed ID: 24993675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
    Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG
    Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
    Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
    J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
    Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
    Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen as induction treatment in resectable head and neck squamous cell carcinoma].
    Zhao XY; Guo Y; Zhu YX; Wang Y; Zhu GP; Hu CS; Ji QH
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Jul; 47(7):536-9. PubMed ID: 22932235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
    de Souza Viana L; de Aguiar Silva FC; Andrade Dos Anjos Jacome A; Calheiros Campelo Maia D; Duarte de Mattos M; Arthur Jacinto A; Elias Mamere A; Boldrini Junior D; de Castro Capuzzo R; Roberto Santos C; Lopes Carvalho A
    Head Neck; 2016 Apr; 38 Suppl 1():E970-80. PubMed ID: 26031625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.